Single-arm phase II trial of pegylated interferon alpha 2a in patients with high-risk essential thrombocythemia or polycythemia vera resistant or intolerant to hydroxyurea: MPN symptom impact & quality of life results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) protocol 111 global phase II trial Meeting Abstract
| Authors: | Dueck, A. C.; Mascarenhas, J.; Kosiorek, H. E.; Yacoub, A.; Prchal, J. T.; Berenzon, D.; Baer, M. R.; Ritchie, E. K.; Silver, R. T.; Kessler, C. M.; Winton, E. F.; Finazzi, M. C.; Rambaldi, A.; Vannucchi, A. M.; Leibowitz, D. S.; Rondelli, D.; Arcasoy, M. O.; Catchatourian, R.; Vadakara, J.; Rosti, V.; Hexner, E.; Kremyanskaya, M.; Orellana, A.; Sandy, L.; Tripodi, J.; Najfeld, V.; Salama, M. E.; Weinberg, R. S.; Rampal, R. K.; Hoffman, R.; Mesa, R. A. |
| Abstract Title: | Single-arm phase II trial of pegylated interferon alpha 2a in patients with high-risk essential thrombocythemia or polycythemia vera resistant or intolerant to hydroxyurea: MPN symptom impact & quality of life results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) protocol 111 global phase II trial |
| Meeting Title: | 59th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 130 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2017 Dec 9-12 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2017-12-07 |
| Language: | English |
| ACCESSION: | WOS:000432419703216 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V130.Suppl_1.4206.4206 |
| Notes: | Meeting Abstract: 4206 -- Source: Wos |
